secwatch.observer — SEC 8-K summary
======================================

Issuer:     Niagen Bioscience, Inc. (NAGE)
CIK:        0001386570
Form:       8-K
Filed at:   2022-11-02T23:59:59+00:00
Accession:  0001628280-22-027801
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ChromaDex Q3 net sales $17.1M, net loss narrows to $1.0M; approaches cash flow breakeven
--------------------------------------------------------------------------------

- Net loss of $1.0M ($0.01 loss per share) vs $8.8M loss in Q3 2021; Adjusted EBITDA loss narrowed to $1.2M.
- Gross margin 59.8% (down from 61.1% YoY); operating expenses cut $6.1M to $13.3M, driven by lower legal and marketing costs.
- Signed long-term supply agreement with Nestlé Health Science with ~$2.0M initial purchase commitment; raised $7.7M from Nestlé and strategic investors.
- JV signed to pursue Blue Hat approval for Tru Niagen in Mainland China; clinical study in JACC found Niagen safe in heart failure patients.
- Tru Niagen e-commerce sales steady but B2B sales declined due to COVID-19 headwinds and macro factors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1386570/000162828022027801/0001628280-22-027801-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1386570/000162828022027801/cdxc-20221102.htm
  HTML page:      https://secwatch.observer/filing/0001628280-22-027801

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer